Repligen (NASDAQ:RGEN) Releases FY 2024 Earnings Guidance

Repligen (NASDAQ:RGEN) updated its FY 2024 earnings guidance on Tuesday. The company provided EPS guidance of 1.500-1.580 for the period, compared to the consensus EPS estimate of 1.430. The company issued revenue guidance of $630.0 million-$639.0 million. Repligen also updated its FY24 guidance to $1.50-1.58 EPS.

Repligen Stock Down 0.8 %

Shares of NASDAQ:RGEN opened at $139.51 on Tuesday. Repligen has a 1 year low of $113.50 and a 1 year high of $211.13. The stock has a 50-day simple moving average of $141.56 and a 200-day simple moving average of $145.05. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The stock has a market capitalization of $7.81 billion, a P/E ratio of -3,487.75, a PEG ratio of 4.04 and a beta of 0.96.

Analysts Set New Price Targets

RGEN has been the subject of several recent research reports. Stephens reissued an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research report on Tuesday, July 30th. Benchmark reissued a “hold” rating on shares of Repligen in a research report on Monday, August 5th. JPMorgan Chase & Co. boosted their price objective on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 31st. UBS Group lowered their target price on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average price target of $190.25.

Insiders Place Their Bets

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.20% of the stock is owned by company insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.